tiprankstipranks
Jazz Pharmaceuticals (MX:JAZZN)
:JAZZN
Mexico Market
JAZZN
Jazz Pharmaceuticals
RESEARCH TOOLSreports

Jazz Pharmaceuticals (JAZZN) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

JAZZN Analyst Ratings

Strong Buy
16Ratings
Strong Buy
16 Buy
0 Hold
0 Sell
Based on 16 analysts giving stock ratings to
Jazz
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

JAZZN Stock 12 Month Forecast

Average Price Target

$5,059.67
▲(69.50% Upside)
Based on 16 Wall Street analysts offering 12 month price targets for Jazz Pharmaceuticals in the last 3 months. The average price target is $5,059.67 with a high forecast of $5,723.12 and a low forecast of $4,602.27. The average price target represents a 69.50% change from the last price of $2,985.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2134":"$2,134","3929":"$3,929","5724":"$5,724","3031.5":"$3,031.5","4826.5":"$4,826.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5723.11663715,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.72K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5059.665331636666,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.06K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4602.268868450001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.60K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2134,3031.5,3929,4826.5,5724],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2985,3195.6243567038464,3406.2487134076923,3616.8730701115387,3827.4974268153846,4038.121783519231,4248.746140223077,4459.370496926924,4669.994853630769,4880.619210334616,5091.243567038462,5301.8679237423075,5512.492280446155,{"y":5723.11663715,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2985,3144.589640895128,3304.1792817902565,3463.7689226853845,3623.358563580513,3782.948204475641,3942.537845370769,4102.1274862658975,4261.717127161026,4421.3067680561535,4580.896408951282,4740.4860498464095,4900.075690741538,{"y":5059.665331636666,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2985,3109.405297573077,3233.810595146154,3358.215892719231,3482.621190292308,3607.0264878653848,3731.4317854384617,3855.837083011539,3980.2423805846156,4104.647678157693,4229.0529757307695,4353.458273303847,4477.863570876923,{"y":4602.268868450001,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2135,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2135,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2135,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2500,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2500,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3100,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2985,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2985,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2985,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2985,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2985,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2985,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2985,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$5,723Average Price Target$5,060Lowest Price Target$4,602
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on MX:JAZZN
Ashwani Verma
UBS
UBS
$5,349.5→$5,723.12
Buy
91.73%
Upside
Assigned
09/14/26
Jazz Pharmaceuticals price target raised to $337 from $315 at UBSJazz Pharmaceuticals price target raised to $337 from $315 at UBS
Barclays Analyst forecast on MX:JAZZN
Etzer Darout
Barclays
Barclays
$4,585.29→$4,602.27
Buy
54.18%
Upside
Reiterated
09/10/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Piper Sandler Analyst forecast on MX:JAZZN
David Amsellem
Piper Sandler
Piper Sandler
$5,264.59
Buy
76.37%
Upside
Reiterated
09/09/26
Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Jazz Pharmaceuticals (JAZZ)
Truist Financial Analyst forecast on MX:JAZZN
Gregory Renza
Truist Financial
Truist Financial
―
Buy
―
Reiterated
09/01/26
Analysts' Top Healthcare Picks: Protagonist Therapeutics (PTGX), PMV Pharmaceuticals (PMVP)
Needham Analyst forecast on MX:JAZZN
Ami Fadia
Needham
Needham
$5,264.59
Buy
76.37%
Upside
Reiterated
08/31/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
TD Cowen Analyst forecast on MX:JAZZN
Joseph Thome
TD Cowen
TD Cowen
$5,094.76
Buy
70.68%
Upside
Reiterated
08/31/26
Analysts Are Bullish on These Healthcare Stocks: Crispr Therapeutics AG (CRSP), Jazz Pharmaceuticals (JAZZ)
Canaccord Genuity Analyst forecast on MX:JAZZN
Gary Nachman
Canaccord Genuity
Canaccord Genuity
$5,094.76
Buy
70.68%
Upside
Reiterated
08/31/26
Jazz Pharmaceuticals: Ziihera’s Strong 1L GEA Profile Supports Reiterated Buy Rating and Unchanged $300 Price Target
RBC Capital Analyst forecast on MX:JAZZN
Leonid Timashev
RBC Capital
RBC Capital
$4,704.16→$5,077.78
Buy
70.11%
Upside
Reiterated
08/28/26
RBC Capital Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)
Morgan Stanley Analyst forecast on MX:JAZZN
Sean Laaman
Morgan Stanley
Morgan Stanley
$4,806.06→$5,468.38
Buy
83.20%
Upside
Assigned
08/26/26
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ), Amneal Pharmaceuticals (NASDAQ: AMRX) and Climb Bio (NASDAQ: CLYM)
Deutsche Bank Analyst forecast on MX:JAZZN
David Hoang
Deutsche Bank
Deutsche Bank
$4,873.99→$5,094.76
Buy
70.68%
Upside
Reiterated
08/26/26
Jazz Pharmaceuticals price target raised to $300 from $287 at Deutsche BankJazz Pharmaceuticals price target raised to $300 from $287 at Deutsche Bank
Bank of America Securities Analyst forecast on MX:JAZZN
Jason Gerberry
Bank of America Securities
Bank of America Securities
$5,213.64
Buy
74.66%
Upside
Reiterated
08/25/26
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ) and GoodRx Holdings (NASDAQ: GDRX)
Wells Fargo Analyst forecast on MX:JAZZN
Mohit Bansal
Wells Fargo
Wells Fargo
$5,094.76
Buy
70.68%
Upside
Reiterated
08/10/26
Wells Fargo Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Stifel Nicolaus Analyst forecast on MX:JAZZN
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
$3,905.98→$4,670.2
Buy
56.46%
Upside
Reiterated
08/04/26
Stifel Nicolaus Remains a Buy on Jazz Pharmaceuticals (JAZZ)
J.P. Morgan Analyst forecast on MX:JAZZN
Jessica Fye
J.P. Morgan
J.P. Morgan
$4,500.37→$4,687.18
Buy
57.02%
Upside
Assigned
08/04/26
Jazz Pharmaceuticals (JAZZ) Receives a Buy from J.P. Morgan
Robert W. Baird Analyst forecast on MX:JAZZN
Brian Skorney
Robert W. Baird
Robert W. Baird
$4,279.6→$4,755.11
Buy
59.30%
Upside
Reiterated
08/04/26
Jazz Pharmaceuticals price target raised to $280 from $252 at BairdJazz Pharmaceuticals price target raised to $280 from $252 at Baird
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on MX:JAZZN
Ashwani Verma
UBS
UBS
$5,349.5→$5,723.12
Buy
91.73%
Upside
Assigned
09/14/26
Jazz Pharmaceuticals price target raised to $337 from $315 at UBSJazz Pharmaceuticals price target raised to $337 from $315 at UBS
Barclays Analyst forecast on MX:JAZZN
Etzer Darout
Barclays
Barclays
$4,585.29→$4,602.27
Buy
54.18%
Upside
Reiterated
09/10/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Piper Sandler Analyst forecast on MX:JAZZN
David Amsellem
Piper Sandler
Piper Sandler
$5,264.59
Buy
76.37%
Upside
Reiterated
09/09/26
Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Jazz Pharmaceuticals (JAZZ)
Truist Financial Analyst forecast on MX:JAZZN
Gregory Renza
Truist Financial
Truist Financial
―
Buy
―
Reiterated
09/01/26
Analysts' Top Healthcare Picks: Protagonist Therapeutics (PTGX), PMV Pharmaceuticals (PMVP)
Needham Analyst forecast on MX:JAZZN
Ami Fadia
Needham
Needham
$5,264.59
Buy
76.37%
Upside
Reiterated
08/31/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
TD Cowen Analyst forecast on MX:JAZZN
Joseph Thome
TD Cowen
TD Cowen
$5,094.76
Buy
70.68%
Upside
Reiterated
08/31/26
Analysts Are Bullish on These Healthcare Stocks: Crispr Therapeutics AG (CRSP), Jazz Pharmaceuticals (JAZZ)
Canaccord Genuity Analyst forecast on MX:JAZZN
Gary Nachman
Canaccord Genuity
Canaccord Genuity
$5,094.76
Buy
70.68%
Upside
Reiterated
08/31/26
Jazz Pharmaceuticals: Ziihera’s Strong 1L GEA Profile Supports Reiterated Buy Rating and Unchanged $300 Price Target
RBC Capital Analyst forecast on MX:JAZZN
Leonid Timashev
RBC Capital
RBC Capital
$4,704.16→$5,077.78
Buy
70.11%
Upside
Reiterated
08/28/26
RBC Capital Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)
Morgan Stanley Analyst forecast on MX:JAZZN
Sean Laaman
Morgan Stanley
Morgan Stanley
$4,806.06→$5,468.38
Buy
83.20%
Upside
Assigned
08/26/26
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ), Amneal Pharmaceuticals (NASDAQ: AMRX) and Climb Bio (NASDAQ: CLYM)
Deutsche Bank Analyst forecast on MX:JAZZN
David Hoang
Deutsche Bank
Deutsche Bank
$4,873.99→$5,094.76
Buy
70.68%
Upside
Reiterated
08/26/26
Jazz Pharmaceuticals price target raised to $300 from $287 at Deutsche BankJazz Pharmaceuticals price target raised to $300 from $287 at Deutsche Bank
Bank of America Securities Analyst forecast on MX:JAZZN
Jason Gerberry
Bank of America Securities
Bank of America Securities
$5,213.64
Buy
74.66%
Upside
Reiterated
08/25/26
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ) and GoodRx Holdings (NASDAQ: GDRX)
Wells Fargo Analyst forecast on MX:JAZZN
Mohit Bansal
Wells Fargo
Wells Fargo
$5,094.76
Buy
70.68%
Upside
Reiterated
08/10/26
Wells Fargo Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Stifel Nicolaus Analyst forecast on MX:JAZZN
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
$3,905.98→$4,670.2
Buy
56.46%
Upside
Reiterated
08/04/26
Stifel Nicolaus Remains a Buy on Jazz Pharmaceuticals (JAZZ)
J.P. Morgan Analyst forecast on MX:JAZZN
Jessica Fye
J.P. Morgan
J.P. Morgan
$4,500.37→$4,687.18
Buy
57.02%
Upside
Assigned
08/04/26
Jazz Pharmaceuticals (JAZZ) Receives a Buy from J.P. Morgan
Robert W. Baird Analyst forecast on MX:JAZZN
Brian Skorney
Robert W. Baird
Robert W. Baird
$4,279.6→$4,755.11
Buy
59.30%
Upside
Reiterated
08/04/26
Jazz Pharmaceuticals price target raised to $280 from $252 at BairdJazz Pharmaceuticals price target raised to $280 from $252 at Baird
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
JAZZJazz Pharmaceuticals
ONCBeOne Medicines
VKTXViking Therapeutics
HROWHarrow Health
KURAKura Oncology
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Jazz Pharmaceuticals

3 Months
Jason GerberryBank of America Securities
Success Rate
18/28 ratings generated profit
64%
Average Return
+3.40%
Copying Jason Gerberry's trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +3.40% per trade.
1 Year
Joseph ThomeTD Cowen
Success Rate
19/21 ratings generated profit
90%
Average Return
+40.25%
Copying Joseph Thome's trades and holding each position for 1 Year would result in 90.48% of your transactions generating a profit, with an average return of +40.25% per trade.
2 Years
Joseph ThomeTD Cowen
Success Rate
20/21 ratings generated profit
95%
Average Return
+72.42%
Copying Joseph Thome's trades and holding each position for 2 Years would result in 95.24% of your transactions generating a profit, with an average return of +72.42% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

JAZZN Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
0
0
0
0
0
Buy
25
31
35
54
48
Hold
2
4
4
2
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
27
35
39
56
48
In the current month, JAZZN has received 48 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. JAZZN average Analyst price target in the past 3 months is 5,059.67.
Each month's total comprises the sum of three months' worth of ratings.

JAZZN Financial Forecast

JAZZN Earnings Forecast

Next quarter’s earnings estimate for JAZZN is $109.93 with a range of $98.71 to $120.84. The previous quarter’s EPS was $97.05. JAZZN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year JAZZN has Performed in-line its overall industry.
Next quarter’s earnings estimate for JAZZN is $109.93 with a range of $98.71 to $120.84. The previous quarter’s EPS was $97.05. JAZZN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year JAZZN has Performed in-line its overall industry.

JAZZN Sales Forecast

Next quarter’s sales forecast for JAZZN is $20.53B with a range of $20.13B to $21.12B. The previous quarter’s sales results were $20.54B. JAZZN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year JAZZN has Performed in-line its overall industry.
Next quarter’s sales forecast for JAZZN is $20.53B with a range of $20.13B to $21.12B. The previous quarter’s sales results were $20.54B. JAZZN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year JAZZN has Performed in-line its overall industry.

JAZZN Stock Forecast FAQ

What is MX:JAZZN’s average 12-month price target, according to analysts?
Based on analyst ratings, Jazz Pharmaceuticals’s 12-month average price target is 5,059.67.
    What is MX:JAZZN’s upside potential, based on the analysts’ average price target?
    Jazz Pharmaceuticals has 69.50% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Jazz Pharmaceuticals a Buy, Sell or Hold?
          Jazz Pharmaceuticals has a consensus rating of Strong Buy, which is based on 16 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Jazz Pharmaceuticals’s share price target?
            The average share price target for Jazz Pharmaceuticals is 5,059.67. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $5,723.12 ,and the lowest forecast is $4,602.27. The average share price target represents 69.50% Increase from the current price of $2,985.
              What do analysts say about Jazz Pharmaceuticals?
              Jazz Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.
                How can I buy shares of Jazz Pharmaceuticals?
                To buy shares of MX:JAZZN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.